HSCS
HeartSciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 3
Consensus Rating "Strong Buy"
MACD Golden Cross
Significant Net Income Decline
EPS Below Expectations
Consecutive Revenue Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About HSCS
Heartsciences Inc.
A medical technology company that provides solutions to understand heart disease
Healthcare Equipment and Supplies
--
06/15/2022
NASDAQ Stock Exchange
15
04-30
Common stock
550 Reserve St, Suite 360, Southlake, Texas 76092
--
HeartSciences Inc., was incorporated in Texas in August 2007. They are a medical technology company focused on applying innovative artificial intelligence-based technologies to electrocardiograms to expand and improve the clinical usefulness of electrocardiograms. Their goal is to make ECG a more valuable cardiac screening tool, especially in front-line or bedside clinical settings. HeartSciences' first FDA-approved product candidate, MyoVistawavECG, is a resting 12-lead electrocardiogram that is also designed to provide diagnostic information related to cardiac dysfunction traditionally only available through the use of cardiac imaging.
Company Financials
EPS
HSCS has released its 2025 Q2 earnings. EPS was reported at -2.27, versus the expected -2.34, beating expectations. The chart below visualizes how HSCS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
HSCS has released its 2026 Q1 earnings report, with revenue of 1.90K, reflecting a YoY change of NaN%, and net profit of -2.05M, showing a YoY change of -0.16%. The Sankey diagram below clearly presents HSCS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
